Nov. 19, 2008-Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that the European Medicines Agency (EMEA) has informally advised that it would maintain its negative opinion on the Company's Marketing Authorization Application (MAA) for SNT-MC17/idebenone in Friedreich's Ataxia.
The details can be read here.
No comments:
Post a Comment